- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05804448
Effet de l'altitude sur la céphalée post-ponction après césarienne
Effet de l'altitude sur la céphalée post-ponction durale après césarienne : une étude de cohorte prospective et multicentrique
The aim of this study is to examine the effects of altitude (high altitude versus low altitude) on incidence and severity of postural puncture headache (PDPH) following spinal anaesthesia for caesarean delivery. The investigators hypothesized that the risk of PDPH would be higher in highlander parturients than in lowlander parturients.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
This will be a prospective cohort study conducted in two different altitudes in Nepal. The high-altitude site is in Jumla, approximately 2514 m above the sea level, and a low altitude city is Dharan, located at 350 m from sea level.
The investigators will screen the eligible participant admitted to the in-patient obstetric unit. The investigator will also record patient baseline characteristics, preoperative anxiety, antenatal depression, presence of chronic pain conditions or preexisting headache. Spinal anaesthesia will be administered in the sitting position at the L3-L4 or L4-L5 interspace using a 25-G pencil point spinal needle (Pencan® 25-gauge).
The diagnosis of post-dural puncture headache will be based on the international headache society ICDH-3 criteria
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Asish Subedi, MD
- Numéro de téléphone: 9842040604
- E-mail: ashish.subedi@bpkihs.edu
Lieux d'étude
-
-
Karnali
-
Jumla, Karnali, Népal, 2069
- Recrutement
- Karnali Academy of Health Sciences
-
Contact:
- Robin Khapung, MD
- Numéro de téléphone: 9849481562
- E-mail: robinkhapung@hotmaail.com
-
-
Koshi
-
Dharān, Koshi, Népal, 56700
- Recrutement
- BP Koirala Institute of Health Sciences (BPKIHS)
-
Contact:
- Asish Subedi, MD
- Numéro de téléphone: 2013 977-25-525555
- E-mail: ashish.subedi@bpkihs.edu
-
Chercheur principal:
- Asish Subedi, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Parturients planned for elective and non-elective (category 2 & 3) caesarean section under spinal anaesthesia.
La description
Inclusion Criteria:
- Parturient, aged more than or equal to 18 years
- American society of Anesthesiologist 2 and 3
- Scheduled for elective and non-elective (category 2 & 3) caesarean delivery with spinal anesthesia
- Native to their resident altitude i.e., those born, raised, and have continuously lived at the same altitude, at least for the past 1 year.
Exclusion Criteria:
- Hypertensive disorder
- Cerebrovascular disease
- Mental disorder (schizophrenia and other psychotic disorders)
- Known fetal anomalies
- Contraindication to spinal anaesthesia.
- Those requiring general anaesthesia for delivery due to failed spinal anesthesia
- Major post-delivery complications (severe haemorrhage, sepsis, or ICU admission)
- Those who migrate from their resident altitude (either low to high or vice versa) within 7 days post-delivery will also be excluded.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
|---|
|
High-altitude group
Parturient who are native to their resident altitude, i.e. residing at the altitude above 2500 m from sea level will receive spinal anesthesia for caesarean section. |
|
Low-altitude group
Parturient who are native to their resident altitude, i.e. residing at the altitude below 500 m from sea level will receive spinal anesthesia for caesarean section. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of patients with postdural puncture headache
Délai: up to 7 days after spinal anesthesia
|
The diagnosis of post-dural puncture headache will be based on the international headache society ICDH-3 criteria: a headache that occurs within 5 days of a dural puncture, is located in the occipital and/or frontal areas, worsens within 15 min of sitting or standing and alleviates within 15 min after lying down, associated with at least one of the following features: neck stiffness, nausea, vomiting, photophobia, and tinnitus, and resolves either spontaneously within 1 week or within 48 h after effective treatment. |
up to 7 days after spinal anesthesia
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of patients with severity of postdural puncture headache
Délai: up to 7 days after spinal anesthesia
|
using a numeric rating scale (NRS), with 0= NO pain 10=worst imaginable pain, and classified as none (NRS=0), mild (1-3), moderate (4-6), and severe (7-10) |
up to 7 days after spinal anesthesia
|
|
Number of patients with non-postdural puncture headache
Délai: up to 7 days after spinal anesthesia
|
Headache that is not related to posture |
up to 7 days after spinal anesthesia
|
|
Number of patients who received treatment for postdural puncture headache
Délai: up to 1 month after occurrence of PDPH
|
paracetamol, NSAID's, caffeine, opioids, glossopharyngeal nerve block, sphenopalatine ganglion block and epidural blood patch |
up to 1 month after occurrence of PDPH
|
Collaborateurs et enquêteurs
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 533/2022 P
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .